Literature DB >> 19363165

alpha1-Adrenergic receptor stimulates interleukin-6 expression and secretion through both mRNA stability and transcriptional regulation: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB.

Dianne M Perez1, Robert S Papay, Ting Shi.   

Abstract

Our previous studies have demonstrated that activation of alpha(1)-adrenergic receptors (ARs) increased interleukin-6 (IL-6) mRNA expression and protein secretion, which is probably an important yet unknown mechanism contributing to the regulation of cardiac function. Using Rat-1 fibroblasts stably transfected with the alpha(1A)-AR subtype and primary mouse neonatal cardiomyocytes, we elucidated the basic molecular mechanisms responsible for the alpha(1)-AR modulation of IL-6 expression. IL-6 mRNA production mediated by alpha(1)-AR peaked at 1 to 2 h. Studies of the mRNA decay rate indicated that alpha(1)-AR activation enhanced IL-6 mRNA stability. Analysis of IL-6 promoter activity using a series of deletion constructs indicated that alpha(1)-ARs enhanced IL-6 transcription through several transcriptional elements, including nuclear factor kappaB (NF-kappaB). Inhibition of alpha(1)-AR mediated IL-6 production and secretion by actinomycin D and the increase of intracellular IL-6 levels by alpha(1)-AR activation suggest that alpha(1)-AR mediated IL-6 secretion through de novo synthesis. Both IL-6 transcription and protein secretion mediated by alpha(1)-ARs were significantly reduced by chemical inhibitors for p38 mitogen-activated protein kinase (MAPK) and NF-kappaB and by a dominant-negative construct of p38 MAPK. Serum level of IL-6 was elevated in transgenic mice expressing a constitutively active mutant of the alpha(1A)-AR subtype but not in a similar mouse model expressing the alpha(1B)-AR subtype. Our results indicate that alpha(1)-ARs stimulated IL-6 expression and secretion through regulating both mRNA transcription and stability, involving p38 MAPK and NF-kappaB pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363165      PMCID: PMC2701459          DOI: 10.1124/mol.108.054320

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  Novel alpha1-adrenergic receptor signaling pathways: secreted factors and interactions with the extracellular matrix.

Authors:  Ting Shi; Zhong-Hui Duan; Robert Papay; Elzbieta Pluskota; Robert J Gaivin; Carol A de la Motte; Edward F Plow; Dianne M Perez
Journal:  Mol Pharmacol       Date:  2006-04-14       Impact factor: 4.436

2.  Systems analysis of PKA-mediated phosphorylation gradients in live cardiac myocytes.

Authors:  Jeffrey J Saucerman; Jin Zhang; Jody C Martin; Lili X Peng; Antine E Stenbit; Roger Y Tsien; Andrew D McCulloch
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-11       Impact factor: 11.205

3.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

4.  Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy.

Authors:  M J Zuscik; S Sands; S A Ross; D J Waugh; R J Gaivin; D Morilak; D M Perez
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

5.  IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes.

Authors:  Nicola Smart; Mart H Mojet; David S Latchman; Michael S Marber; Michael R Duchen; Richard J Heads
Journal:  Cardiovasc Res       Date:  2005-10-10       Impact factor: 10.787

6.  p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system.

Authors:  R Craig; A Larkin; A M Mingo; D J Thuerauf; C Andrews; P M McDonough; C C Glembotski
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

7.  Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis.

Authors:  Kenichi Matsushita; Shiro Iwanaga; Takahiro Oda; Kensuke Kimura; Megumi Shimada; Makoto Sano; Akihiro Umezawa; Jun-ichi Hata; Satoshi Ogawa
Journal:  Lab Invest       Date:  2005-10       Impact factor: 5.662

8.  alpha1A- but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism.

Authors:  Boyd R Rorabaugh; Sean A Ross; Robert J Gaivin; Robert S Papay; Dan F McCune; Paul C Simpson; Dianne M Perez
Journal:  Cardiovasc Res       Date:  2005-02-01       Impact factor: 10.787

9.  The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism.

Authors:  R Winzen; M Kracht; B Ritter; A Wilhelm; C Y Chen; A B Shyu; M Müller; M Gaestel; K Resch; H Holtmann
Journal:  EMBO J       Date:  1999-09-15       Impact factor: 11.598

10.  Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase.

Authors:  S Kumar; M S Jiang; J L Adams; J C Lee
Journal:  Biochem Biophys Res Commun       Date:  1999-10-05       Impact factor: 3.575

View more
  29 in total

1.  A-kinase-anchoring protein-Lbc connects stress signaling to cardiac hypertrophy.

Authors:  F Donelson Smith; John D Scott
Journal:  Mol Cell Biol       Date:  2012-11-12       Impact factor: 4.272

2.  α1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages.

Authors:  Laurel A Grisanti; Andrew P Woster; Julie Dahlman; Edward R Sauter; Colin K Combs; James E Porter
Journal:  J Pharmacol Exp Ther       Date:  2011-05-13       Impact factor: 4.030

3.  The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo.

Authors:  Monte S Willis; Amro Ilaiwy; Megan D Montgomery; Paul C Simpson; Brian C Jensen
Journal:  Metabolomics       Date:  2016-09-15       Impact factor: 4.290

Review 4.  The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension.

Authors:  Revathy Carnagarin; Vance Matthews; Maria T K Zaldivia; Karlheinz Peter; Markus P Schlaich
Journal:  Br J Pharmacol       Date:  2018-09-25       Impact factor: 8.739

5.  Role of NF-κB and p38 MAPK activation in mediating angiotensin II and endothelin-1-induced stimulation in leptin production and cardiomyocyte hypertrophy.

Authors:  Venkatesh Rajapurohitam; Ana Kilic; Sabzali Javadov; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2012-04-20       Impact factor: 3.396

6.  Novel proteins associated with human dilated cardiomyopathy: selective reduction in α(1A)-adrenergic receptors and increased desensitization proteins.

Authors:  Ting Shi; Christine S Moravec; Dianne M Perez
Journal:  J Recept Signal Transduct Res       Date:  2013-02-06       Impact factor: 2.092

7.  A-kinase-anchoring protein-Lbc anchors IκB kinase β to support interleukin-6-mediated cardiomyocyte hypertrophy.

Authors:  Cosmo Damiano del Vescovo; Susanna Cotecchia; Dario Diviani
Journal:  Mol Cell Biol       Date:  2012-10-22       Impact factor: 4.272

8.  α₁A-adrenergic receptors regulate cardiac hypertrophy in vivo through interleukin-6 secretion.

Authors:  Robert S Papay; Ting Shi; Michael T Piascik; Sathyamangla V Naga Prasad; Dianne M Perez
Journal:  Mol Pharmacol       Date:  2013-02-12       Impact factor: 4.436

9.  NF-κB and androgen receptor variant expression correlate with human BPH progression.

Authors:  David C Austin; Douglas W Strand; Harold L Love; Omar E Franco; Alex Jang; Magdalena M Grabowska; Nicole L Miller; Omar Hameed; Peter E Clark; Jay H Fowke; Robert J Matusik; Ren J Jin; Simon W Hayward
Journal:  Prostate       Date:  2015-12-28       Impact factor: 4.104

10.  Interleukin-6 amplifies glucagon secretion: coordinated control via the brain and pancreas.

Authors:  Tammy M Barnes; Yolanda F Otero; Amicia D Elliott; Alicia D Locke; Carlo M Malabanan; Anastasia G Coldren; Marcela Brissova; David W Piston; Owen P McGuinness
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-09-09       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.